G
Global Blood Therapeutics
A clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities
About Global Blood Therapeutics
Global Blood Therapeutics (GBT), now part of Pfizer, is dedicated to discovering, developing, and delivering innovative treatments for sickle cell disease (SCD), a lifelong inherited blood disorder affecting hemoglobin in red blood cells. GBT's core product, Oxbryta (voxelotor), has been approved by the U.S. FDA for SCD patients as young as 4 years old. The company operates in the biopharmaceutical sector, primarily serving patients, their families, and healthcare professionals. GBT's business model focuses on research and development, clinical trials, and regulatory approvals to bring new therapies to market. Revenue is generated through the sale of its approved treatments and potential future therapies. GBT is committed to changing the treatment paradigm in SCD through continuous innovation and strong community advocacy.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2012
- Headquarters
- San Francisco, United States
- Employees
- 73
- Open positions
- None listed
- Dealroom signal
- 63.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Verified Unicorns and $1B Exits, Post IPO $1B, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Aug 2022 | $5.4B | $5.4B | Pfizer | ↗ |
| IPO✓Exit | Aug 2015 | $120M | $350M | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Global Blood Therapeutics is 800 monthly website visits, up 90.5% over the last three months. Global Blood Therapeutics's team declined 24% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Third Rock Ventures
Deerfield
Sabby Capital
RA Capital Management
Wellington Management
Other known investors4 additional known investors
Pfizer
Aisling Capital
Avoro Capital Advisors
Perceptive Advisors
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Global Blood Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Global Blood Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.